how big is Granules India?

As of Jun 06, Granules India Ltd has a market capitalization of 12,902.11 Cr, with recent net sales of 4,481.61 Cr and a net profit of 501.51 Cr over the last four quarters.

Market Cap: Granules India Ltd has a market capitalization of 12,902.11 Cr and is classified as a Mid Cap company as of Jun 06.<BR><BR>Recent Quarterly Performance: The company reported a sum of Net Sales for the latest 4 quarters amounting to 4481.61 Cr and a sum of Net Profit of 501.51 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: This is Consolidated data for the latest annual period ending in Mar'24. Shareholder's Funds are reported at 3,225.54 Cr, and Total Assets stand at 5,483.88 Cr.

When is the next results date for Granules India?

No Upcoming Board Meetings

Who are in the management team of Granules India?

As of March 2023, the management team of Granules India includes C Krishna Prasad (Chairman & Managing Director), KVS Ram Rao (Joint Managing Director & CEO), and several independent and non-executive directors, responsible for guiding the company's strategic direction and operations.

As of March 2023, the management team of Granules India includes:<BR><BR>1. C Krishna Prasad - Chairman & Managing Director<BR>2. A Arun Rao Akinepally - Non-Executive & Independent Director<BR>3. Harsha Chigurupati - Executive Director<BR>4. Uma Devi Chigurupati - Executive Director<BR>5. K B Sankara Rao - Non-Executive & Non-Independent Director<BR>6. Chaitanya Tummala - Company Secretary & Compliance Officer<BR>7. Arun Sawhney - Non-Executive & Independent Director<BR>8. Saumen Chakraborty - Independent Director<BR>9. Sucharita Rao Palepu - Independent Director<BR>10. KVS Ram Rao - Joint Managing Director & CEO<BR>11. Kapil Mehan - Independent Director<BR><BR>This diverse team is responsible for guiding the company's strategic direction and operations.

Has Granules India declared dividend?

Granules India Ltd has declared a 150% dividend, amounting to ₹1.5 per share, with an ex-date of July 30, 2024. The company has shown strong long-term performance, with total returns of 190.17% over the past five years.

Granules India Ltd has declared a 150% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 150%<BR>- Amount per share: 1.5<BR>- Ex-date: Jul-30-2024<BR><BR>Dividend Yield: 0.28%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -8.15%, with a dividend return of 0%, resulting in a total return of -8.15%.<BR><BR>Over the past year, the price return was 13.06%, with a dividend return of 0.32%, leading to a total return of 13.38%.<BR><BR>In the 2-year period, the price return was 87.46%, and the dividend return was 1.02%, giving a total return of 88.48%.<BR><BR>For the 3-year period, the price return was 94.13%, with a dividend return of 1.57%, resulting in a total return of 95.7%.<BR><BR>In the last 4 years, the price return was 61.48%, and the dividend return was 1.66%, culminating in a total return of 63.14%.<BR><BR>Over the past 5 years, the price return was 187.16%, with a dividend return of 3.01%, leading to a total return of 190.17%.<BR><BR>Overall, Granules India has declared a significant dividend, and the total returns over various periods show a strong performance, particularly over the long term, indicating a positive outlook for investors.

Who are the peers of the Granules India?

Granules India's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. In terms of management risk and growth, Sun Pharma, Cipla, and Dr Reddy's Labs perform excellently, while Granules India shows good management risk but below-average growth, with a 1-year return of 18.66%.

Peers: The peers of Granules India are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alivus Life, Sanofi Consumer, Marksans Pharma, P & G Health Ltd, and Ami Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, Alivus Life, Marksans Pharma, P & G Health Ltd, and Granules India. Average management risk is present at Ami Organics. Growth is excellent at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Alivus Life, Granules India, and Marksans Pharma. The capital structure is excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Alivus Life, Granules India, Marksans Pharma, and P & G Health Ltd, while good capital structure is noted at Torrent Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Ami Organics at 86.64%, while the lowest is Sanofi Consumer, which has no available data. Granules India has a 1-year return of 18.66%, which is lower than Ami Organics but higher than Sanofi Consumer. Additionally, Torrent Pharma and Marksans Pharma have negative six-month returns.

What does Granules India do?

Granules India Ltd is a vertically integrated pharmaceutical company that manufactures Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD). As of March 2025, it reported net sales of ₹11,974 Cr and a net profit of ₹1,520 Cr.

Overview:<BR>Granules India Ltd is a large-scale vertically integrated company in the Pharmaceuticals & Biotechnology industry, specializing in the manufacturing of Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI), and Finished Dosage (FD).<BR><BR>History:<BR>Granules India Ltd was founded on March 18th, 1991. The company has maintained its status as a leader in the off-patent drugs segment and reported its latest quarterly results for March 2025, showcasing significant sales and profit figures.<BR><BR>Financial Snapshot:<BR>- Net Sales: 11,974 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 1,520 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: INR 11,897 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 26.00<BR>- Industry P/E: 37<BR>- Dividend Yield: 0.30%<BR>- Debt-Equity: 0.23<BR>- Return on Equity: 12.86%<BR>- Price to Book: 3.22<BR><BR>Contact Details:<BR>Address: Second Floor Block III, My Home Hub Madhapur Hyderabad Telangana : 500081<BR>Tel: 91-40-66760000<BR>Email: investorrelations@granulesindia.com<BR>Website: http://www.granulesindia.com

Who are the top shareholders of the Granules India?

The top shareholders of Granules India include promoter Krishna Prasad Chigurupati with 31.65%, mutual funds at 12.24%, foreign institutional investors at 13.24%, and Life Insurance Corporation of India as the largest public shareholder with 5.33%. Individual investors collectively own 16.54% of the shares.

The top shareholders of Granules India include the promoters, who hold the majority of the shares. The promoter with the highest holding is Krishna Prasad Chigurupati, owning 31.65% of the company. Additionally, mutual funds hold 12.24% through 28 schemes, while foreign institutional investors (FIIs) have a stake of 13.24% across 150 entities. The highest public shareholder is Life Insurance Corporation of India, which holds 5.33%. Individual investors collectively own 16.54% of the shares.

Are Granules India latest results good or bad?

Granules India's latest results show a mixed performance: while net sales reached a five-quarter high at Rs 1,210.10 crore and cash reserves improved, the company faced a 25.91% decline in consolidated net profit and a slight decrease in operating profit, indicating both strengths and challenges.

Granules India’s latest financial results present a mixed picture. On the positive side, the company achieved its highest quarterly net sales in the last five quarters, totaling Rs 1,210.10 crore, which indicates a favorable trend in sales. Additionally, their cash and cash equivalents reached Rs 596.38 crore, the highest in the last six half-yearly periods, suggesting improved short-term liquidity.<BR><BR>However, there are notable challenges as well. The company experienced a significant decline in consolidated net profit, down by 25.91% compared to the previous quarter, and its operating profit also saw a slight decrease. Furthermore, while the increase in non-operating income to Rs 16.35 crore is noteworthy, it raises concerns about the sustainability of this income source.<BR><BR>Overall, while there are some positive indicators, the decline in profit margins and the mixed performance suggest that Granules India is facing both strengths and challenges in its current financial situation.

Is Granules India overvalued or undervalued?

As of November 6, 2025, Granules India is fairly valued with a PE ratio of 28.14, an EV to EBITDA of 15.28, and a ROCE of 15.74%, making it more attractive compared to peers like Sun Pharma and Divi's Lab, despite a recent stock return of -4.20% against the Sensex, while showing a significant long-term gain of 290.73% over the past decade.

As of 6 November 2025, Granules India has moved from an expensive to a fair valuation grade. The company is currently fairly valued based on its valuation metrics. Key ratios include a PE ratio of 28.14, an EV to EBITDA of 15.28, and a ROCE of 15.74%. <BR><BR>In comparison to its peers, Granules India’s PE ratio is lower than Sun Pharma's 35.02 and Divi's Lab's 79.09, indicating a more attractive valuation relative to these companies. Additionally, while Granules India has a PEG ratio of 0.00, indicating potential for growth, it is worth noting that its dividend yield stands at a modest 0.27%. Despite recent underperformance against the Sensex over the past year, with a stock return of -4.20% compared to the Sensex's 3.65%, the long-term performance over the last decade shows a substantial gain of 290.73%.

How has been the historical performance of Granules India?

Granules India has experienced fluctuating net sales and profits, peaking at 4,511.92 Cr in March 2023 before a slight decline by March 2025, while operating profit increased to 958.16 Cr due to reduced raw material costs. The company showed resilience with growth in total assets and improved cash flow from operating activities, despite variations in profit before and after tax.

Answer:<BR>The historical performance of Granules India shows a fluctuating trend in net sales and profits over the years, with a notable increase in recent periods.<BR><BR>Breakdown:<BR>Granules India's net sales peaked at 4,511.92 Cr in March 2023 but slightly declined to 4,481.61 Cr by March 2025. The total operating income followed a similar pattern, reaching 4,511.92 Cr in March 2023 and then decreasing to 4,481.61 Cr in March 2025. The raw material costs decreased significantly from 2,352.65 Cr in March 2023 to 1,724.94 Cr in March 2025, contributing to an operating profit (PBDIT) of 958.16 Cr in March 2025, up from 927.60 Cr in March 2023. However, profit before tax showed fluctuations, with a high of 687.17 Cr in March 2023, dropping to 660.17 Cr in March 2025. The profit after tax also varied, recording 516.60 Cr in March 2023 and 501.52 Cr in March 2025. The company's total assets increased from 4,903.14 Cr in March 2023 to 6,184.73 Cr in March 2025, while total liabilities rose from 4,903.14 Cr to 6,184.73 Cr in the same period. Cash flow from operating activities improved to 866 Cr in March 2025, compared to 738 Cr in March 2023, indicating a positive trend in cash generation. Overall, Granules India has shown resilience in its financial performance, with significant growth in assets and operating profits despite some fluctuations in sales and profits.

Is Granules India technically bullish or bearish?

As of December 1, 2025, Granules India has shifted to a bullish trend with moderate strength, supported by bullish indicators like the MACD and Bollinger Bands, although caution is advised due to mildly bearish monthly MACD and KST signals.

As of 1 December 2025, the technical trend for Granules India has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this include a bullish MACD on the weekly chart, bullish Bollinger Bands on both weekly and monthly time frames, and a bullish daily moving average. However, the monthly MACD and KST remain mildly bearish, indicating some caution. The stock has shown a strong performance over the past three years compared to the Sensex, further supporting the bullish outlook.

Should I buy, sell or hold Granules India?

Which are the latest news on Granules India?

Why is Granules India falling/rising?

As of 04-Dec, Granules India Ltd's stock price is rising to 568.00, reflecting a positive trend supported by strong fundamentals, efficient management, and consistent returns, despite a decline in investor participation. The stock is trading above its moving averages and is considered fairly valued compared to peers.

As of 04-Dec, Granules India Ltd's stock price is rising, currently at 568.00, reflecting a change of 0.4 (0.07%) upward. This increase can be attributed to several factors. Firstly, the stock has shown a positive performance over the past week, gaining 3.40%, while the benchmark Sensex has declined by 0.53%. Additionally, Granules India is trading above its moving averages across various time frames, indicating a bullish trend.<BR><BR>Moreover, the company demonstrates strong management efficiency with a high Return on Capital Employed (ROCE) of 17.70%, and a low Debt to EBITDA ratio of 0.97 times, suggesting a solid ability to service its debt. The stock is also considered fairly valued compared to its peers, trading at a discount to average historical valuations. Over the past year, it has generated a return of 4.70%, with profits rising by 4.6%, which supports its attractiveness as an investment.<BR><BR>However, it is important to note that there has been a decline in investor participation, with delivery volume falling by 57.45% against the 5-day average. Despite this, the stock remains liquid enough for trading, which may contribute to its price stability. Overall, the combination of strong fundamentals, consistent returns over the last three years, and high institutional holdings at 32.01% likely supports the stock's upward movement.